Coronavirus (COVID-19) vaccination rates for people aged 18 years and over in England. Estimates by socio-demographic characteristic, region and local authority.

Vaccinations in London Between 8 December 2020 and 15 September 2021 5,838,305 1st doses and 5,232,885 2nd doses have been administered to London residents. Differences in vaccine roll out between London and the Rest of England London Rest of England Priority Group Vaccinations given Percentage vaccinated Vaccinations given Percentage vaccinated Group 1 Older Adult Care Home Residents 21,883 95% 275,964 96% Older Adult Care Home Staff 29,405 85% 381,637 88% Group 2 80+ years 251,021 83% 2,368,284 93% Health Care Worker 174,944 99% 1,139,243 100%* Group 3 75 - 79 years 177,665 90% 1,796,408 99% Group 4 70 - 74 years 252,609 90% 2,454,381 97% Clinically Extremely Vulnerable 278,967 88% 1,850,485 95% Group 5 65 - 69 years 285,768 90% 2,381,250 97% Group 6 At Risk or Carer (Under 65) 983,379 78% 6,093,082 88% Younger Adult Care Home Residents 3,822 92% 30,321 93% Group 7 60 - 64 years 373,327 92% 2,748,412 98% Group 8 55 - 59 years 465,276 91% 3,152,412 97% Group 9 50 - 54 years 510,132 90% 3,141,219 95% Data as at 15 September 2021 for age based groups and as at 12 September 2021 for non-age based groups * The number who have received their first dose exceeds the latest official estimate of the population for this group There is considerable uncertainty in the population denominators used to calculate the percentage vaccinated. Comparing implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following datasets can be used to estimate vaccine uptake by age group for London: ONS 2020 mid-year estimates (MYE). This is the population estimate used for age groups throughout the rest of the analysis. Number of people ages 18 and over on the National Immunisation Management Service (NIMS) ONS Public Health Data Asset (PHDA) dataset. This is a linked dataset combining the 2011 Census, the General Practice Extraction Service (GPES) data for pandemic planning and research and the Hospital Episode Statistics (HES). This data covers a subset of the population. Vaccine roll out in London by Ethnic Group Understanding how vaccine uptake varies across different ethnic groups in London is complicated by two issues: Ethnicity information for recipients is unavailable for a very large number of the vaccinations that have been delivered. As a result, estimates of vaccine uptake by ethnic group are highly sensitive to the assumptions about and treatment of the Unknown group in calculations of rates. For vaccinations given to people aged 50 and over in London nearly 10% do not have ethnicity information available, The accuracy of available population denominators by ethnic group is limited. Because ethnicity information is not captured in official estimates of births, deaths, and migration, the available population denominators typically rely on projecting forward patterns captured in the 2011 Census. Subsequent changes to these patterns, particularly with respect to international migration, leads to increasing uncertainty in the accuracy of denominators sources as we move further away from 2011. Comparing estimated population sizes and implied vaccination rates for multiple sources of denominators provides some indication of uncertainty in the true values. Confidence is higher where the results from multiple sources agree more closely. Because the denominator sources are not fully independent of one another, users should interpret the range of values across sources as indicating the minimum range of uncertainty in the true value. The following population estimates are available by Ethnic group for London:

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

The number and percentage of Covid-19 fully vaccinated people by age band. Population estimates are based on National Immunisation Management Service counts.This dataset has been updated to reflect new age bandings and population figures provided in July 2022.This dataset now includes details of the Autumn Booster programme.Note on analysis:This datasets presents the proportion of the eligible population who have received all vaccinations they are entitled to. This is terms as a "Complete Dose". The number of vaccinations required to qualify as a complete dose differs by the age of the individual. The following scale is used to determine this:- Aged 5 - 15 - Dose 1- Aged 16 - 24 - Dose 1 & Dose 2- Aged 35 - 50 - Dose 1, Dose 2 & Booster- Aged 50+ - Dose1, Dose2, Booster & Autumn BoosterData is updated weekly.

These data describe pneumococcal polysaccharide vaccine (PPV) uptake for the survey year, for those aged 65 years and over.RationaleVaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Pneumococcal disease is a significant cause of morbidity and mortality. Certain groups are at risk for severe pneumococcal disease, these include young children, the elderly and people who are in clinical risk groups2. Pneumococcal infections can be non invasive such as bronchitis, otitis media or invasive such as septicaemia, pneumonia, meningitis. Cases of invasive pneumococcal infection usually peak in the winter during December and January. The pneumococcal polysaccharide vaccine (PPV) protects against 23 types of Streptococcus pneumoniae bacterium. It is thought that the PPV is around 50 percent to 70 percent effective at preventing more serious types of invasive pneumococcal infection2.Since 1992 the 23 valent PPV has been recommended for people in the clinical risk groups and since 2003, the PPV vaccination programme has expanded to include immunisation to all those aged 65 years and over in England1This indicator was judged to be a valid and an important measure of public health and was therefore included in the public health outcomes framework. Inclusion of these indicators will encourage the continued prioritisation and evaluation and the effectiveness of the PPV vaccination programme and give an indication of uptake at an upper tier Local Authority level. The vaccination surveys measure the proportion of eligible people that have received PPV at any time and the proportion that received PPV during the previous year, providing an opportunity to assess the delivery of the immunisation programme11 Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2013 to March 2014 [online]. 2015 [cited 2015 Mar]. Available from URL: https://www.gov.uk/government/publications/pneumococcal-polysaccharide-vaccine-ppv-vaccine-coverage-estimates 2 Pneumococcal infections, NHS Choices [online]. 2013 [cited 2013 Dec]. Available from URL: http://www.nhs.uk/conditions/vaccinations/pages/pneumococcal-vaccination.aspxDefinition of numeratorUKHSA provided UTLA level data. Clinical commissioning group (CCG) data is available from https://www.gov.uk/government/collections/vaccine-uptake#ppv-vaccine-uptakeDefinition of denominatorNumber of adults aged 65 years and over. Data from 2013 to 2014 are now available at source at a local authority level. Data prior to 2013 to 2014 were collected at a PCT level and converted to LA level for inclusion in PHOF using the criteria as defined below:Denominators for local authorities are estimated from denominators for PCTs. Denominators for PCTs include all people registered with practices accountable to the PCT, and no data are available to provide resident-based figures. Denominators for local authorities are estimated as follows: (For local authorities that have exactly the same boundary as a PCT, the PCT figure is used as it is the only estimate available for the residents of the PCT and local authority. For local authorities whose boundary is contained wholly within a single PCT, but is not equal to the whole PCT, the LA denominator is estimated as a proportion of the PCT figure, with the exceptions of Isles of Scilly, City of London, Rutland, Cornwall, Hackney and Leicestershire (see below). For local authorities whose boundaries include all or part of more than one PCT, the local authority denominator is estimated by aggregating the appropriate proportions of the denominators for the PCTs whose boundaries include part of the local authority. The appropriate proportions in cases ii and iii are defined according to the resident population (in the appropriate age group) in the calendar year overlapping most of the period of the indicator value (or the most recent available): resident population by Lower Layer Super Output Area were extracted and used to calculate the population resident in every LA PCT overlapping block.To calculate the denominator, each LA PCT overlap is calculated as a proportion of the PCT resident population, and then multiplied by the denominator for the PCT. A LA may overlap several PCTs: the appropriate portions of all the PCTs’ denominators are aggregated to give the denominator estimate for the LA. Expressed as an equation the denominator is calculated as follows: DenominatorLA = ∑ (DenominatorPCT × n/N) summed over all PCTs overlapping the LA where: DenominatorLA = Estimated denominator in the LA n = Population resident in the LA-PCT overlapping block N = Population resident in the PCT DenominatorPCT = Denominator in the PCT For Isles of Scilly, City of London and Rutland, no indicator data are presented (prior to 2013 to 2014), as the local authority makes up a very small proportion of the PCT, and estimates for the LAs based on the PCT figures are unlikely to be representative as they are swamped by the much larger local authority within the same PCT. The estimates for Cornwall, Hackney and Leicestershire local authorities are combined data for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland respectively in order to ensure that all valid PCT data are included in the England total.Denominators for Cornwall and Isles of Scilly, City of London and Hackney, and Leicestershire and Rutland are not combined for the 2019 to 2020 annual local authority level data."CaveatsThe pneumococcal vaccine uptake collection is a snapshot of GP patients vaccinated currently registered at the time of data extraction. The proportion of GP practices who provided data for the surveys are available from the uptake reports. Data will exclude patients who have received the vaccine but have subsequently died, patients who have since moved, or patients that are vaccinated but have not had their electronic patient record updated by the time of data extraction. Data for local authorities prior to 2013 to 2014 have been estimated from registered PCT level indicators. While the majority of patients registered with practices accountable to a PCT tend to be resident within that PCT, there are, in some PCTs, significant differences between their resident and registered populations. Therefore the estimates for LAs may not always accurately reflect the resident population of the local authority (LA). Please note that the PCT response rate should be checked for data completeness as this will have a knock on effect to the LA values.

Figures on coronavirus (COVID-19) vaccine uptake in school pupils aged 12 to 17 years attending state-funded secondary, sixth form and special schools, broken down by demographic and geographic characteristics, using a linked English Schools Census and National Immunisation Management System dataset. Experimental Statistics.

Covid vaccinations administered by local area since 8th December 2020. It includes the calculated percentage of the 12+ population who have received all required vaccinations and/or boosters.Population estimates are based on National Immunisation Management Service counts.

Children for whom the local authority is responsible who completed a booster course of diphtheria, tetanus, pertussis, polio (DTaP and IPV) vaccine at any time by their fifth birthday as a percentage of all children whose fifith birthday falls within the time period.RationaleA booster vaccine for diphtheria, tetanus, pertusiss and polio disease has been in the routine childhood immunisation programme since late 2001. It is currently offered at 3 year and 4 months or soon after. Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children in LA responsible population whose fifth birthday falls within the time period who received a DTaP and IPV booster at any time before their fifth birthday.Definition of denominatorTotal number of children in LA responsible population whose fifth birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Data are extracted directly from local population registers, and data issues are generally related to underestimation of coverage. There may be some overestimation of denominators due to children who have moved away remaining on the area register, which can lead to underestimates of coverage. In some areas, it is known that a small number of GPs do not submit vaccination data to the local CHIS, also resulting in underestimation of coverage. Using non-standardised data extraction methods could result in overestimated coverage.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

We aimed to examine the long-term correlation between influenza vaccination coverage and the incidence of influenza-like illness (ILI) in the total and elderly populations of European countries for which data was available on at least six consecutive influenza seasons. We graphically visualised vaccination coverage and ILI incidence trends and calculated Spearman rank correlation coefficients. Additionally, we fitted a negative binomial regression model to estimate the change in ILI incidence per percentage point change in vaccination coverage. We found significant negative correlations for the total population of the Netherlands (ρ = -0.60, p-value = 0.003) and for the elderly populations of England (ρ = -0.80, p-value < 0.001) and Germany (ρ = -0.57, p-value = 0.04). However, results were not consistent, and for some countries we observed significant positive correlations. Only for the elderly in England was there a significant decline in incidence rate per percentage point increase in vaccination coverage (incidence rate ratio = 0.93; 95% confidence interval 0.88–0.99). Based on this ecological study it is not possible to provide evidence for a negative correlation between influenza vaccination coverage and ILI incidence. For future, aetiological studies to assess impact of influenza vaccinations on the population, there is a need for high quality data over long periods of time, on proportion of ILI caused by influenza virus infection, on severe outcome measures such as hospitalisation for influenza, and on other factors that potentially affect influenza transmission.

Children for whom the local authority is responsible who completed a course of Meningococcal group B (MenB) vaccine at any time by their first birthday as a percentage of all children whose first birthday falls within the time period.RationaleThe MenB vaccine protects against invasive meningococcal disease caused by capsule group B, which most commonly presents as septicaemia, meningitis, or a combination of both. The vaccine was introduced into the routine childhood immunisation programme in September 2015 for babies at 8 and 16 weeks of age, with a booster dose after the first birthday.Vaccination coverage is the best indicator of the level of protection a population has against vaccine-preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage helps identify possible drops in immunity before disease levels rise. The MenB vaccine is given to all children under two years old as part of the childhood vaccination programme.Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. This may also be relevant for NICE guidance PH21: Reducing differences in the uptake of immunisations, which aims to increase immunisation uptake among those under 19 years from groups where uptake is low.Definition of numeratorTotal number of children in LA responsible population whose first birthday falls within the time period who received two doses of MenB at any time before their first birthday.Definition of denominatorTotal number of children in LA responsible population whose first birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA. For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.MenB primary data are available as National Statistics for the first time in 2017 to 2018. Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

This data originates from the Public Health Outcomes tool currently presents data for available indicators for upper tier local authority levels, collated by Public Health England (PHE). The data currently published here are the baselines for the Public Health Outcomes Framework, together with more recent data where these are available. The baseline period is 2010 or equivalent, unless these data are unavailable or not deemed to be of sufficient quality. The first data were published in this tool as an official statistics release in November 2012. Future official statistics updates will be published as part of a quarterly update cycle in August, November, February and May. The definition, rationale, source information, and methodology for each indicator can be found within the spreadsheet. Data included in the spreadsheet: 0.1i - Healthy life expectancy at birth0.1ii - Life Expectancy at 650.1ii - Life Expectancy at birth0.2i - Slope index of inequality in life expectancy at birth based on national deprivation deciles within England0.2ii - Number of upper tier local authorities for which the local slope index of inequality in life expectancy (as defined in 0.2iii) has decreased0.2iii - Slope index of inequality in life expectancy at birth within English local authorities, based on local deprivation deciles within each area0.2iv - Gap in life expectancy at birth between each local authority and England as a whole0.2v - Slope index of inequality in healthy life expectancy at birth based on national deprivation deciles within England0.2vii - Slope index of inequality in life expectancy at birth within English regions, based on regional deprivation deciles within each area1.01i - Children in poverty (all dependent children under 20)1.01ii - Children in poverty (under 16s)1.02i - School Readiness: The percentage of children achieving a good level of development at the end of reception1.02i - School Readiness: The percentage of children with free school meal status achieving a good level of development at the end of reception1.02ii - School Readiness: The percentage of Year 1 pupils achieving the expected level in the phonics screening check1.02ii - School Readiness: The percentage of Year 1 pupils with free school meal status achieving the expected level in the phonics screening check1.03 - Pupil absence1.04 - First time entrants to the youth justice system1.05 - 16-18 year olds not in education employment or training1.06i - Adults with a learning disability who live in stable and appropriate accommodation1.06ii - % of adults in contact with secondary mental health services who live in stable and appropriate accommodation1.07 - People in prison who have a mental illness or a significant mental illness1.08i - Gap in the employment rate between those with a long-term health condition and the overall employment rate1.08ii - Gap in the employment rate between those with a learning disability and the overall employment rate1.08iii - Gap in the employment rate for those in contact with secondary mental health services and the overall employment rate1.09i - Sickness absence - The percentage of employees who had at least one day off in the previous week1.09ii - Sickness absence - The percent of working days lost due to sickness absence1.10 - Killed and seriously injured (KSI) casualties on England's roads1.11 - Domestic Abuse1.12i - Violent crime (including sexual violence) - hospital admissions for violence1.12ii - Violent crime (including sexual violence) - violence offences per 1,000 population1.12iii- Violent crime (including sexual violence) - Rate of sexual offences per 1,000 population1.13i - Re-offending levels - percentage of offenders who re-offend1.13ii - Re-offending levels - average number of re-offences per offender1.14i - The rate of complaints about noise1.14ii - The percentage of the population exposed to road, rail and air transport noise of 65dB(A) or more, during the daytime1.14iii - The percentage of the population exposed to road, rail and air transport noise of 55 dB(A) or more during the night-time1.15i - Statutory homelessness - homelessness acceptances1.15ii - Statutory homelessness - households in temporary accommodation1.16 - Utilisation of outdoor space for exercise/health reasons1.17 - Fuel Poverty1.18i - Social Isolation: % of adult social care users who have as much social contact as they would like1.18ii - Social Isolation: % of adult carers who have as much social contact as they would like1.19i - Older people's perception of community safety - safe in local area during the day1.19ii - Older people's perception of community safety - safe in local area after dark1.19iii - Older people's perception of community safety - safe in own home at night2.01 - Low birth weight of term babies2.02i - Breastfeeding - Breastfeeding initiation2.02ii - Breastfeeding - Breastfeeding prevalence at 6-8 weeks after birth2.03 - Smoking status at time of delivery2.04 - Under 18 conceptions2.04 - Under 18 conceptions: conceptions in those aged under 162.06i - Excess weight in 4-5 and 10-11 year olds - 4-5 year olds2.06ii - Excess weight in 4-5 and 10-11 year olds - 10-11 year olds2.07i - Hospital admissions caused by unintentional and deliberate injuries in children (aged 0-14 years)2.07i - Hospital admissions caused by unintentional and deliberate injuries in children (aged 0-4 years)2.07ii - Hospital admissions caused by unintentional and deliberate injuries in young people (aged 15-24)2.08 - Emotional well-being of looked after children2.09i - Smoking prevalence at age 15 - current smokers (WAY survey)2.09ii - Smoking prevalence at age 15 - regular smokers (WAY survey)2.09iii - Smoking prevalence at age 15 - occasional smokers (WAY survey)2.09iv - Smoking prevalence at age 15 years - regular smokers (SDD survey)2.09v - Smoking prevalence at age 15 years - occasional smokers (SDD survey)2.12 - Excess Weight in Adults2.13i - Percentage of physically active and inactive adults - active adults2.13ii - Percentage of physically active and inactive adults - inactive adults2.14 - Smoking Prevalence2.14 - Smoking prevalence - routine & manual2.15i - Successful completion of drug treatment - opiate users2.15ii - Successful completion of drug treatment - non-opiate users2.16 - People entering prison with substance dependence issues who are previously not known to community treatment2.17 - Recorded diabetes2.18 - Admission episodes for alcohol-related conditions - narrow definition2.19 - Cancer diagnosed at early stage (Experimental Statistics)2.20i - Cancer screening coverage - breast cancer2.20ii - Cancer screening coverage - cervical cancer2.21i - Antenatal infectious disease screening – HIV coverage2.21iii - Antenatal Sickle Cell and Thalassaemia Screening - coverage2.21iv - Newborn bloodspot screening - coverage2.21v - Newborn Hearing screening - Coverage2.21vii - Access to non-cancer screening programmes - diabetic retinopathy2.21viii - Abdominal Aortic Aneurysm Screening2.22iii - Cumulative % of the eligible population aged 40-74 offered an NHS Health Check2.22iv - Cumulative % of the eligible population aged 40-74 offered an NHS Health Check who received an NHS Health Check2.22v - Cumulative % of the eligible population aged 40-74 who received an NHS Health check2.23i - Self-reported well-being - people with a low satisfaction score2.23ii - Self-reported well-being - people with a low worthwhile score2.23iii - Self-reported well-being - people with a low happiness score2.23iv - Self-reported well-being - people with a high anxiety score2.23v - Average Warwick-Edinburgh Mental Well-Being Scale (WEMWBS) score2.24i - Injuries due to falls in people aged 65 and over2.24ii - Injuries due to falls in people aged 65 and over - aged 65-792.24iii - Injuries due to falls in people aged 65 and over - aged 80+3.01 - Fraction of mortality attributable to particulate air pollution3.02 - Chlamydia detection rate (15-24 year olds)3.02 - Chlamydia detection rate (15-24 year olds)3.03i - Population vaccination coverage - Hepatitis B (1 year old)3.03i - Population vaccination coverage - Hepatitis B (2 years old)3.03iii - Population vaccination coverage - Dtap / IPV / Hib (1 year old)3.03iii - Population vaccination coverage - Dtap / IPV / Hib (2 years old)3.03iv - Population vaccination coverage - MenC3.03ix - Population vaccination coverage - MMR for one dose (5 years old)3.03v - Population vaccination coverage - PCV3.03vi - Population vaccination coverage - Hib / Men C booster (5 years)3.03vi - Population vaccination coverage - Hib / MenC booster (2 years old)3.03vii - Population vaccination coverage - PCV booster3.03viii - Population vaccination coverage - MMR for one dose (2 years old)3.03x - Population vaccination coverage - MMR for two doses (5 years old)3.03xii - Population vaccination coverage - HPV3.03xiii - Population vaccination coverage - PPV3.03xiv - Population vaccination coverage - Flu (aged 65+)3.03xv - Population vaccination coverage - Flu (at risk individuals)3.04 - People presenting with HIV at a late stage of infection3.05i - Treatment completion for TB3.05ii - Incidence of TB3.06 - NHS organisations with a board approved sustainable development management plan3.07 - Comprehensive, agreed inter-agency plans for responding to health protection incidents and emergencies4.01 - Infant mortality4.02 - Tooth decay in children aged 54.03 - Mortality rate from causes considered preventable4.04i - Under 75 mortality rate from all cardiovascular diseases4.04ii - Under 75 mortality rate from cardiovascular diseases considered preventable4.05i - Under 75 mortality rate from cancer4.05ii - Under 75 mortality rate from cancer considered preventable4.06i - Under 75 mortality rate from liver disease4.06ii - Under 75 mortality rate from liver disease considered preventable4.07i - Under 75 mortality rate from respiratory disease4.07ii - Under 75 mortality rate from respiratory disease considered preventable4.08 - Mortality

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

Children for whom the local authority is responsible who completed a booster course of Meningococcal group B (MenB) vaccine at any time by their second birthday as a percentage of all children whose second birthday falls within the time period.RationaleThe MenB vaccine protects against invasive meningococcal disease capsule group B most commonly presenting as either septicaemia or meningitis, or a combination of both. The vaccine was introduced into the routine childhood immunisation programme in September 2015 for babies at 8 and 16 weeks of age, with a booster dose after the first birthday. Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise. The MenB vaccine is given to all children under two years old as part of the childhood vaccination programme. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels. May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorTotal number of children in LA responsible population whose second birthday falls within the time period who received a MenB booster at any time before their second birthday.Definition of denominatorTotal number of children in LA responsible population whose second birthday falls within the time period. Coverage figures are supplied for patients registered with GPs based in that LA and for unregistered patients who were resident in that LA. The LA responsible population is therefore different from the estimated resident population figures produced by the Office of National Statistics (ONS) for each LA.For the COVER collection, the LA responsible population is usually derived from the population registers held on CHISs.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental and should be treated with caution as it is not an official statistic.MenB booster data will be available as National Statistics for the first time in 2018 to 2019. Information on childhood immunisation coverage at ages one, two, and five is collected through the UK COVER collection by UKHSA. These aggregated data are collected from CHISs, computerised systems storing clinical records that support health promotion and prevention activities for children, including immunisation. In England, COVER data are collected for Upper Tier Local Authorities (LAs) using the COVER data collection form. These are established collections based on total populations, not samples.The number of CHIS systems has decreased from over 100 in 2015 to around 70 by mid-2017. As different phases of the digital strategy are implemented across the country, it is anticipated that there may be further temporary local data quality issues associated with the transition. Temporary data quality issues in some London COVER returns during 2017 to 2018 were observed in the quarterly COVER reports as the new Hubs became responsible for generating coverage data. Changes in vaccine coverage within London should therefore be interpreted with caution for the time being.Data are extracted directly from local population registers, and data issues are generally related to underestimation of coverage. There may be some overestimation of denominators due to children who have moved away remaining on the area register, which can lead to underestimates of coverage. In some areas, it is known that a small number of GPs do not submit vaccination data to the local CHIS, also resulting in underestimation of coverage. Using non-standardised data extraction methods could result in overestimated coverage.Caution should be exercised when comparing coverage figures over time due to occasional data quality issues reported by some data suppliers. Apparent trends could reflect changes in the quality of data reported as well as real changes in vaccination coverage. While this issue will be more apparent at the local level, it may also impact national figures. Similarly, some caution should be exercised when comparing coverage between different areas where data quality issues have been reported.

All persons aged 13 to 14 years who have received the second (completing) dose of the HPV vaccine within each reporting area (local authority LA) as a percentage of all persons aged 13 to 14 years within each areaRationaleThe national human papillomavirus (HPV) immunisation programme was introduced in 2008 for secondary school year 8 females (12 to 13 years of age) to protect them against the main causes of cervical cancer. While it was initially a three dose vaccination programme, it was run as a two dose schedule from September 2014 following expert advice.The first HPV vaccine dose is usually offered to females in Year 8 (aged 12 to 13 years) and the second dose 12 months later in Year 9, but some local areas have scheduled the second dose from six months after the first. Therefore the completed course coverage is not available until the end of Year 9.From September 2019, 12 to 13 year old males became eligible for HPV immunisation alongside females, based on JCVI advice.Definition of numeratorNumber of persons in school year 9 (aged 13 to 14) who have received the second dose of HPV vaccine within each LA.Definition of denominatorNumber of year 9 (aged 13 to 14) persons in each LA.CaveatsOn 23 March 2020, all educational settings in England were advised to close by the UK Government as part of COVID19 pandemic measures. Although the importance of maintaining good vaccine uptake was impressed, operational delivery of all school aged immunisation programmes was paused for a short period of time as a consequence of school closures limiting access to venues for providers and children who were eligible for vaccination.The NHSEI central public health commissioning and operations team rapidly established an Immunisation Task and Finish Group, with regional NHSEI and PHE representation. The group was established to:assess the impact of COVID19 on all immunisation programmes, including school aged programmesdevelop technical guidance and a plan for restoration and recovery of school aged programmes, once education settings were re openedFrom 1 June 2020 some schools partially re-opened for some year groups for a mini summer term. NHSEI published clinical guidance for healthcare professionals on maintaining immunisation programmes during COVID19, and the Department of Education published further guidance which led to schools allowing vaccination sessions to resume on site. NHSEI commissioned, school aged immunisation providers were able to implement their restoration and recovery plans to commence catch up during the summer of 2020. This included delivery of programmes in school and community settings following a robust risk assessment and in line with UK government public health COVID19 guidance. The aim was to ensure that those eligible for HPV vaccination had been offered at least one dose of vaccine in line with JCVI recommendations with the second dose scheduled at a later date.In September 2020, schools across the UK reopened for general in person attendance. During the 2020 to 2021 academic year, students were required to stay at home and learn remotely if they tested positive for COVID 19 or if they were a contact of a confirmed COVID19 case and so school attendance rates in England were lower than normal, especially in areas with very high COVID19 incidence rates. In England, as part of a wider national lockdown in January 2021, schools were closed to all, except children of keyworkers and vulnerable children. From early March 2021, primary schools reopened, with a phased reopening of secondary schools.Although this led to some disruption of school-based immunisation programme delivery in the 2020 to 2021 academic year, NHSEI Regional Public Health Commissioning teams worked with NHSEI commissioned school aged immunisation providers to maintain the delivery of the routine programme and catch up. As the routine programme is commissioned for a school aged cohort rather than a school based cohort, providers were able to build on existing arrangements such as community based clinics in place for home school children. A wide variety of local arrangements were established to ensure programme delivery continued effectively and safely in the school and community premises, during the term time and school breaks.

All children for whom the local authority is responsible who received two doses of MMR on or after their first birthday and at any time up to their fifth birthday as a percentage of all children whose fifth birthday falls within the time period.RationaleMMR is the combined vaccine that protects against measles, mumps and rubella. Measles, mumps and rubella are highly infectious, common conditions that can have serious complications, including meningitis, swelling of the brain (encephalitis) and deafness. They can also lead to complications in pregnancy that affect the unborn baby and can lead to miscarriage.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The first MMR vaccine is given to children as part of the routine vaccination schedule, usually within a month of their first birthday. They'll then have a booster dose before starting school, which is usually between three and five years of age. Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels.May also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorTotal number of children whose fifth birthday falls within the time period who received two doses of MMR on or after their first birthday and at any time before their fifth birthday.Data for 2013 to 2014 are available at source at LA level. Data prior to 2013 to 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.Definition of denominatorTotal number of children whose fifth birthday falls within the time period.Data from 2013 and 2014 are available at source at LA level. Data prior to 2013 and 2014 were collected at PCT level and converted to LA level using the criteria as described in the notes section below.CaveatsFull GP postcodes are used to aggregate data to ICB. The GP-level coverage data is collected by NHS Digital Strategic Data Collection Service (SDCS) and published by the UK Health Security Agency (UKHSA) COVER team. ICB data is experimental data and should be treated with caution. It is not an official statistic.

Shingles vaccine coverage for adults of GP registered population turning 71 between 1 April to 31 March, and vaccinated by the following end of June.RationaleThe shingles vaccination programme was introduced to reduce the incidence and severity of shingles in those targeted by the programme by boosting individuals’ pre-existing VZV immunity. The shingles vaccine stimulates individual pre-existing immunity, which cannot be acquired naturally, so immunisation is required for protection.In 2010, the UK’s Joint Committee on Vaccination and Immunisation (JCVI) recommended that a herpes zoster (shingles) vaccination programme should be introduced for adults aged 70 years, with a catch-up programme for those aged 71 to 79 years.In April 2017, eligibility criteria for the shingles vaccination were revised so that adults become eligible for the routine programme on their 70th birthday and remain eligible until their 80th birthday. Following this change, from 2018 to 2019, vaccine coverage is measured in those aged 71 and is calculated as the total number of patients who turned 71 between 1 April and 31 March, and were vaccinated by the end of June, as a proportion of the number of patients that turned 71 years old between 1 April and 31 March.Prior to this (2013 to 2014 to 2017 to 2018), the vaccine was routinely offered to adults aged 70 years on 1 September of the programme year. Vaccine coverage was calculated as the total number of patients aged 70 on 1 September who had ever received the vaccination (numerator) as a proportion of the number of patients registered aged 70 years on 1 September (denominator) as of the following August.Due to the changes in the vaccination coverage collection described, data for this indicator are not comparable to the previous shingles indicator D06c: shingles vaccination coverage among 70-year-olds, available from 2013 to 2014 to 2017 to 2018.Reference:Shingles (herpes zoster): the green book, chapter 28.Definition of numeratorNumber of patients registered with a GP practice with 71st birthday within the financial year that received a shingles vaccination by the end of the June. The age and timing of the extraction for the numerator are different to the numerator describe in submissions prior to 2018 and 2019 in the D06c Population vaccination coverage: Shingles (70 years old) indicator. The numerators from these two indicators should not be compared.Definition of denominatorNumber of patients registered with a GP practice in each LA whose 71st birthday is within the financial year. The age and timing of the extraction for the denominator are different to the denominator describe in submissions prior to 2018 and 2019 in the D06c Population vaccination coverage: Shingles (70 years old) indicator. The denominators from these two indicators should not be compared.CaveatsAggregated GP practice level shingles vaccine coverage data is automatically uploaded via participating GP IT suppliers to the ImmForm website on a quarterly basis, and these data in turn are aggregated to LA level. The proportion of participating practices is currently at least 95 percentof all GP practices in England. Therefore, number of registered patients aged 71 years in each LA is based on participating practices only. Where less than 100 percent of practices in an LA participate the number of registered patients will not represent the true total in that LA and therefore vaccine coverage may not be truly representative of that LA.

This dataset provides information on the percentage of people aged 65 and over who received a seasonal flu vaccination. It covers vaccinations administered during the influenza season, which runs from 1st September to the end of February. The data supports public health efforts to monitor and improve flu vaccine uptake among older adults, a group particularly vulnerable to complications from influenza. The dataset is sourced from official government vaccine uptake records.

Rationale

The indicator aims to increase the uptake of seasonal flu immunisations among individuals aged 65 and over. This supports broader public health goals to reduce the burden of influenza-related illness and hospitalisation in older populations.

Numerator

The numerator is the number of flu vaccinations administered to individuals aged 65 and over during the influenza season, from 1st September to the end of February. This data is collected through the GOV Seasonal Flu Vaccine Uptake programme.

Denominator

The denominator is the GP-registered population aged 65 and over on the date of data extraction. It includes all eligible individuals, including those who were offered the vaccine but declined it, ensuring the uptake rate reflects the entire target population.

Caveats

Data collection relies on Read codes used in GP systems to identify patients in clinical risk groups eligible for vaccination. Limitations may arise from incomplete coding or delays in data entry. Additionally, the dataset may not capture all eligible individuals if their records are not updated in time.

External references

OHID Fingertips: Seasonal Flu Vaccinations in Over 65s

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.

This dataset reports on the uptake of seasonal flu vaccinations among children aged 2 to 3 years old in England. It reflects the percentage of children in this age group who received the flu vaccine between 1st September and the end of February, as recorded in GP systems. The data supports public health efforts to increase childhood immunisation rates and reduce the spread of influenza in early years settings.

Rationale

The rationale for this indicator is to increase childhood immunisation coverage by age 2, focusing on flu vaccination for children aged 2 and 3. Early vaccination helps protect young children from influenza and contributes to broader community immunity.

Numerator

The numerator is the number of flu vaccinations administered to children aged 2 and 3 years during the influenza season, from 1st September to the end of February. This data is collected through the GOV Seasonal Flu Vaccine Uptake programme.

Denominator

The denominator is the GP-registered population of children aged 2 and 3 years as of 31st August. It includes all eligible children, including those who were offered the vaccine but declined it. The age cut-off aligns with the academic school year.

Caveats

The data represents a final percentage based on responses from all participating GP practices in England. National totals are derived from the GP practice sample and are not extrapolated. Data collection depends on accurate and timely updates to GP records.

External references

OHID Fingertips: Flu Immunisation in Children

Localities ExplainedThis dataset contains data based on either the resident locality or registered locality of the patient, a distinction is made between resident locality and registered locality populations:Resident Locality refers to individuals who live within the defined geographic boundaries of the locality. These boundaries are aligned with official administrative areas such as wards and Lower Layer Super Output Areas (LSOAs).Registered Locality refers to individuals who are registered with GP practices that are assigned to a locality based on the Primary Care Network (PCN) they belong to. These assignments are approximate—PCNs are mapped to a locality based on the location of most of their GP surgeries. As a result, locality-registered patients may live outside the locality, sometimes even in different towns or cities.This distinction is important because some health indicators are only available at GP practice level, without information on where patients actually reside. In such cases, data is attributed to the locality based on GP registration, not residential address.

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.

This dataset reports the percentage of children who received a booster dose of the Haemophilus influenzae type b (Hib) and Meningococcal group C (MenC) vaccines before their second birthday. The data is collected through the UK Health Security Agency’s (UKHSA) Cover of Vaccination Evaluated Rapidly (COVER) programme and reflects immunisation coverage across England. It is a key indicator of early childhood protection against serious infectious diseases.

Rationale Ensuring high vaccination coverage by age two is critical for protecting children against preventable diseases such as Hib and MenC, which can cause severe illness including meningitis and septicaemia. Monitoring booster uptake helps identify areas with lower coverage and supports targeted public health interventions to improve immunisation rates and reduce health inequalities.

Numerator The numerator is the total number of children whose second birthday falls within the reporting period and who received a booster dose of Hib and MenC at any time before their second birthday. This data is sourced from the UKHSA’s COVER programme.

Denominator The denominator is the total number of children whose second birthday falls within the same reporting period, also sourced from the COVER programme.

Caveats Data at the Integrated Care Board (ICB) level is considered experimental and should be interpreted with caution. It is not classified as an official statistic and may be subject to revisions or methodological changes.

External References NHS Digital – Immunisation Statistics

Click here to explore more from the Birmingham and Solihull Integrated Care Partnerships Outcome Framework.